Ranitidine and the incidence of hypersensitivity reactions to paclitaxel: A retrospective cohort study

Paclitaxel is a commonly used chemotherapeutic agent. To minimize the risk of hypersensitivity reactions (HSRs), which occur in approximately 16–42% of patients, premedication with dexamethasone, clemastine, and ranitidine was standard of care. As of October 2019, ranitidine is no longer available....

Descripción completa

Detalles Bibliográficos
Autores principales: Haine, Anouk I., Notenboom, Cornelia (Marije) A. W., Tan, Liong (Vincent) P., Ruiter, Rikje, van der Deure, Wendy M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271659/
https://www.ncbi.nlm.nih.gov/pubmed/35811355
http://dx.doi.org/10.1002/prp2.985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271659/
https://www.ncbi.nlm.nih.gov/pubmed/35811355
http://dx.doi.org/10.1002/prp2.985

Ejemplares similares